S-CEI of Nexium in Paediatric Patients

Specific Clinical Experience Investigation of Nexium in Paediatric Patients

To capture safety and efficacy when Nexium are administered to pediatric patients in clinical practice after launch

The objective of this investigation is to capture the followings when Nexium capsules or Nexium granules for suspension (single-dose package) are administered to pediatric patients in clinical practice after launch.

1. Development of adverse reactions which are unexpected from Precaution for Use
2. Development of adverse reactions
3. Efficacy

Inclusion Criteria:

• Patients aged 1(inclusive) to 15 (exclusive) years
• Patients who have been prescribed Nexium for the first time for "gastric ulcer", "duodenal ulcer", "anastomotic ulcer", "reflux oesophagitis", "non-erosive reflux disease", or "Zollinger-Ellison syndrome", .

Exclusion Criteria:

• Patients with a history of hypersensitivity to components contained in this product.
• Patients during treatment with Atazanavir Sulfate and Rilpivirine hydrochloride.